Janghee Woo
YOU?
Author Swipe
View article: Scalable, Antibody-Free Lipid Nanoparticle Achieves Human HSPC-Selective mRNA Delivery In Vivo Without Conditioning
Scalable, Antibody-Free Lipid Nanoparticle Achieves Human HSPC-Selective mRNA Delivery In Vivo Without Conditioning Open
Cell and gene therapies for hematologic malignancies currently rely on mobilization, apheresis, ex vivo genetic manipulation, and reinfusion of engineered cells. This multistep process is associated with significant logistical and clinical…
View article: Genome-wide characterization of clonal hematopoiesis reveals extensive non-coding putative driver mutations
Genome-wide characterization of clonal hematopoiesis reveals extensive non-coding putative driver mutations Open
As humans age, we acquire somatic mutations in our blood, leading to clonal hematopoiesis (CH). Despite the prevalence of clonal hematopoiesis (CH) in aged individuals, recent searches for selective sweeps in single-cell derived colonies h…
View article: Predictors of response and rational combinations for the novel <scp>MCL</scp> ‐1 inhibitor <scp>MIK665</scp> in acute myeloid leukemia
Predictors of response and rational combinations for the novel <span>MCL</span> ‐1 inhibitor <span>MIK665</span> in acute myeloid leukemia Open
Despite promising anti‐leukemic activity of MCL‐1 inhibitors in preclinical studies of acute myeloid leukemia (AML), clinical progress has been hindered by limited knowledge of target patient subgroups. To stratify patients for MCL‐1 inhib…
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Network-Based Stratification Refines Stratification of Intermediate-Risk Acute Myeloid Leukemia Samples
Network-Based Stratification Refines Stratification of Intermediate-Risk Acute Myeloid Leukemia Samples Open
The European LeukemiaNet (ELN) risk stratification of acute myeloid leukemia (AML) uses genetic and molecular markers to categorize patients. However, disease heterogeneity, particularly in the intermediate-risk group, complicates stratifi…
View article: Systematic review and meta-analysis on fully automated digital cognitive behavioral therapy for insomnia
Systematic review and meta-analysis on fully automated digital cognitive behavioral therapy for insomnia Open
Insomnia impairs daily functioning and increases health risks. Cognitive behavioral therapy for insomnia (CBT-I) is effective but limited by cost and therapist availability. Fully automated digital CBT-I (FA dCBT-I) provides an accessible …
View article: Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia Open
Despite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of acute myeloid leukemia (AML), their progress through clinical evaluation has in part been challenged by limited knowledge of patient subgroups suitable …
View article: Fine-Tuned Anti-CD19 CAR-T Cells to Improve Anti-Tumor Activity By Smash Platform
Fine-Tuned Anti-CD19 CAR-T Cells to Improve Anti-Tumor Activity By Smash Platform Open
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking advancement in the field of immunotherapy, offering new hope for patients with certain types of hematologic malignancies such as B-cell lymphomas and acute ly…
View article: Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia Open
Background Elevated MCL-1 expression has been shown to play a central role in apoptosis escape and to mediate primary resistance to the approved BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) (Li, 2019). Preclinical investigati…
View article: Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The most common CH mutations occur in the DNMT3A and TET2 genes and result in in…
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.